한국버섯학회지 (Journal of Mushroom)

  • 제19권1호
  • /
  • Pages.23-32
  • /
  • 2021
  • /
  • 1738-0294(pISSN)
  • /
  • 2288-8853(eISSN)
한국버섯학회 (The Korean Society of Mushroom Science)
권호 표지
DOI QR코드

DOI QR Code

고지방과 고콜레스테롤 식이 급여에 의해 고지혈증이 유도된 흰쥐에서 꽃송이버섯 자실체의 항고지혈증과 항비만 효과

Anti-hyperlipidemic and anti-obesity effects of Sparassis latifolia fruiting bodies in high-fat and cholesterol-diet-induced hyperlipidemic rats

  • 임경환 (인천대학교 생명과학부) ;
  • 백승아 (인천대학교 생명과학부) ;
  • 최재혁 (인천대학교 생명과학부) ;
  • 이태수 (인천대학교 생명과학부)
  • Im, Kyung-Hoan (Division of Life Sciences, Incheon National University (Songdo-dong)) ;
  • Baek, Seung-A (Division of Life Sciences, Incheon National University (Songdo-dong)) ;
  • Choi, Jaehyuk (Division of Life Sciences, Incheon National University (Songdo-dong)) ;
  • Lee, Tae-Soo (Division of Life Sciences, Incheon National University (Songdo-dong))
  • 투고 : 2020.12.01
  • 심사 : 2021.03.24
  • 발행 : 2021.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

꽃송이버섯의 자실체가 고지방과 고콜레스테롤을 급여한 Sprague-Dawley계 암컷 흰쥐의 지질대사와 비만에 미치는 효과를 조사하기 위해 생후 6주령의 흰쥐에 정상 식이를 급여한 군(ND), 정상 식이에 20%의 돈지(Lard)와 1%의 콜레스테롤을 첨가하여 급여한 군(HFD), HFD 식이에 꽃송이버섯 자실체 분말을 5% 수준으로 첨가하여 급여한 군(HFD+SL), HFD 식이에 simvastatin을 0.3% 수준으로 첨가하여 급여한 군(HFD+SS) 등 4개의 실험군으로 나누어 6주간 실험을 진행하였다. 각각의 실험군 간 체중의 증가율은 HFD+SL군과 HFD+SS군이 HFD군에 비해 유의하게 감소하여 ND군와 유사한 수준을 나타내 HFD 식이에 꽃송이버섯을 첨가하여 급여한 HFD+SL군의 비만이 억제되었다. ND군의 식이섭취량은 HFD군에 비해 유의하게 높았고 HFD+SL군과 HFD+SS군에 비해서는 고도로 유의하게 높았다. 혈청 총콜레스테롤(TC), 저밀도지단백질 콜레스테롤(LDL-C) 및 중성지방(TG)의 농도는 HFD군에 비해 ND군, HFD+SL군 및 HFD+SS군이 유의하게 낮았다. 심혈관계 질환의 위험도를 나타내는 동맥경화지수(AI)와 LDL-C/HDL-C 비율도 HFD군에 비해 ND군, HFD+SL군 및 HFD+SS군이 유의하게 낮아 꽃송이버섯 자실체의 급여가 심혈관계 질환의 발생 위험도를 낮출 수 있은 것으로 나타났다. 알부민, 크레아티닌, 요산 및 총단백질의 농도는 모든 실험군 간 정상적인 수치를 나타냈으나 혈당 농도는 HFD군에 비해 ND군, HFD+SL군, HFD+SS군 모두 유의하게 낮아 꽃송이버섯이 혈당을 낮추는 효과가 있었다. 간 기능 손상의 척도를 나타내는 AST와 ALT 효소의 활성은 모든 실험군 간 유의성은 없었으나 ALP 효소의 농도는 HFD에 비해 ND군와 HFD+SL군 및 HFD+SS군이 유의하게 낮아 꽃송이버섯을 첨가한 식이의 급여가 흰쥐의 ALP 농도를 유의하게 낮추는 효과가 있었다. 실험 5주와 6주 사이에 배출된 분변의 총 지질과 콜레스테롤의 양을 측정한 결과 HFD+SL군이 배출한 총 지질과 콜레스테롤의 양이 HFD군과 HFD+SS군에 비해 유의하게 높게 나타나 HFD식이에 함유된 일부의 지질과 콜레스테롤이 꽃송이버섯에 의해 장내로 흡수되지 않고 분변으로 배출된 것으로 나타났다. 각각의 실험군의 간 조직을 적출하여 oil red O로 염색하고 현미경으로 관찰한 결과 HFD군에서는 심한 지방간이 관찰되었으나 HFD+SS군은 ND군과 같이 지방간이 전혀 관찰되지 않았고 HFD+SL군의 간 조직에서는 소량의 지방 방울이 관찰되어 꽃송이버섯의 자실체에는 비알코올성지방간을 억제하는 효과가 있는 것으로 나타났다. 따라서 꽃송이버섯 자실체는 고지방과 고콜레스테롤 식이 섭취로 인해 발생하는 체중증가, 혈청의 콜레스테롤과 중성지방농도 및 비알코올성 지방간의 개선에 효과가 있어 심혈관계 질환과 비만의 예방과 치료에 도움을 줄 수 있을 것으로 판단된다.

This study investigated the anti-hyperlipidemic and anti-obesity effects of Sparassis latifolia (S. latifolia) fruiting body powder in rats fed with a high fat and cholesterol diet (HFD). Rats were fed a normal control diet (ND), an HFD, an HFD supplemented with 5% fruiting body powder of S. latifolia (HFD+SL), or an HFD supplemented with 0.03% simvastatin (HFD+SS), for 6 weeks. The HFD group demonstrated considerable increase in body weight gain, the food efficiency ratio (FER), and plasma cholesterol and triglyceride levels, compared to the ND group. In contrast, the HFD+SL and HFD+SS groups showed significantly reduced body weight gain, food intake, and plasma cholesterol and triglyceride levels compared to the HFD group. In particular, the HFD+SL and HFD+SS diets significantly suppressed the occurrence of non-alcoholic fat deposits in the liver. Taken together, these results suggest that dietary supplementation of the fruiting body powder of S. latifolia in an HFD could lower the risks of hyperlipidemia, atherogenesis, and obesity and may be used as a functional food to manage cardiovascular disease and fecal lipid and cholesterol levels.

키워드

참고문헌

  1. Agah HM, Alipour A, Janbozorgi M, Hajihosseini R, Shaghaghi F, Golchin N, Nouhi S. 2013. Lipid profile improvement after four group psychological interventions in combination to nutritional and physical activity instructing among overweight and obese individuals. Iran J Public Health 42: 86-95.
  2. Alam N, Yoon KN, Lee TS, Lee UY. 2011. Hypolipidemic activities of dietary Pleurotus ostreatus in hypercholesterolemic rats. Mycobiol 39: 45-51. https://doi.org/10.4489/MYCO.2011.39.1.045
  3. Cannon CP. 2007. Cardiovascular disease and modifiable cardiometabolic risk factors. Clin Cornerstone 8: 11-28. https://doi.org/10.1016/S1098-3597(07)80025-1
  4. Chandrasekaran G, Oh DS, Shin HJ. 2011. Properties and potential applications of the culinary-medicinal cauliflower mushroom, Sparassis crispa Wulf.:Fr. (Aphyllophoromycetideae): A review. Int J Med Mushrooms 13: 177-183. https://doi.org/10.1615/IntJMedMushr.v13.i2.100
  5. Cheung PCK. 1996. The hypercholesterolemic effect of two edible mushrooms: Auricularia auricula (tree-ear) and Tremella fuciformis (white jelly-leaf) in hypercholesterolemic rats. Nutr Res 16: 1721-1725. https://doi.org/10.1016/0271-5317(96)00191-1
  6. Choi MH, Han HK, Lee YJ, Jo HG, Shin HJ. 2014. In vitro anticancer activity of hydrophobic fractions of Sparassis latifolia extract using AGS, A529, and HepG2 cell lines. J Mushroom 12: 304-310. https://doi.org/10.14480/JM.2014.12.4.304
  7. Dai YC, Wang Z, Binder M, Hibbett DS. 2006. Phylogeny and a new species of Sparassis (Polyporales, Basidiomycota): Evidence from mitochondrial atp6, nuclear rDNA and rpb2 genes. Mycologia 98: 584-592. https://doi.org/10.3852/mycologia.98.4.584
  8. Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497-509. https://doi.org/10.1016/S0021-9258(18)64849-5
  9. Gordon DT. 1992. The importance of total dietary fiber in human nutrition and health. Kor J Nutr 25: 75-83.
  10. Haglund O, Loustarinen R, Wallin R, Wibell I, Saldeen T. 1991. The effect of oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. J Nutr 121(2): 165-169. https://doi.org/10.1093/jn/121.2.165
  11. Jones P, Kafonek S, Laurora I, Hunninghake D. 1998. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81: 582-587. https://doi.org/10.1016/s0002-9149(97)00965-x
  12. Kim GY, Jung HW, Kim EJ. 2013. Anti-hyperlipidemic effect of shiitake mushroom extract in hyperlipidemic rats induced by Poloxamer-407. Korean J Orient Pathol 27: 409-415.
  13. Kim JH, Son IS, Kim JS, Kim KH, Kwon CS. 2008. Lipase inhibitory and anti-oxidative activity of the methanol extract and the powder of Phellinus linteus. J Korean Soc Food Sci Nutr 37: 154-161. https://doi.org/10.3746/JKFN.2008.37.2.154
  14. Kobayashi H, Matsushita M, Oda K, Nishikimi N, Sakuri T, Komori K. 2004. Effect of atherosclerotic plaque on the enlargement of an experimental model of abdominal aortic aneurysm in rabbits. Eur J Vasc Endovasc Surg 28: 71-78. https://doi.org/10.1016/j.ejvs.2004.03.015
  15. Lee MA, Park JK, Um MH, Jeon JW, Lee JM, Park YK. 2012. Lipolytic effect of Sparassis crispa extracts in differentiated 3T3-L1 cells and high fat diet-induced obese mice. J Korean Soc Food Sci Nutr 41: 1708-1715. https://doi.org/10.3746/JKFN.2012.41.12.1708
  16. Lee MR, Hou JG, Begum S, Wang YB, Oh DS, Wi AJ, Yoon BS, Sung CK. 2014. Anti-obesity effects of Sparassis crispa on high-fat diet-induced obese mice. J Life Sci 24: 952-958. https://doi.org/10.5352/JLS.2014.24.9.952
  17. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA. 2006. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation 114: 82-96. https://doi.org/10.1161/CIRCULATIONAHA.106.176158
  18. Liu S, Stampfer MJ, Hu FB. 1999. Whole-grain consumption and risk of coronary heart disease: Results from the nurses' health study. Am J Clin Nutr 70: 412-419. https://doi.org/10.1093/ajcn/70.3.412
  19. Ma X, Li Z. 2006. Pathogenesis of nonalcoholic steatohepatitis (NASH). Chin J Dig Dis 7: 7-11. https://doi.org/10.1111/j.1443-9573.2006.00237.x
  20. Manzi P, Pizzoferrato L. 2000. Beta-glucans in edible mushrooms. Food Chem 68: 315-318. https://doi.org/10.1016/S0308-8146(99)00197-1
  21. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. 2002. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 87: 1451-1458. https://doi.org/10.1210/jcem.87.4.8412
  22. Mattilda P, Konko K, Eurola M, Pihlava JM, Astola J, Vahteristo L. 2001. Contents of vitamins, mineral elements, and some phenolic compounds in cultivated mushrooms. J Agric Food Chem 49: 2343-2348. https://doi.org/10.1021/jf001525d
  23. Mattilda P, Suonpaa K, Piironen V. 2000. Functional properties of edible mushrooms. Nutrition 16: 694-696. https://doi.org/10.1016/S0899-9007(00)00341-5
  24. Molitoris HP. 1994. Mushrooms in medicine. Folia Microbiol 9: 91-98. https://doi.org/10.1007/BF02906801
  25. Moradali MF, Mostafavi H, Ghods S, Hedjaroude GA. 2007. Immunomodulating and anticancer agents in the realm of macromycetes fungi (macrofungi). Int Immunopharmacol 7: 701-724. https://doi.org/10.1016/j.intimp.2007.01.008
  26. Mori K, Kobayashi C, Tomita T, Inatomi S, Ikeda M. 2008. Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (Eringi), Grifola frondosa (Maitake), and Hypsizygus marmoreus (Bunashimeji) in apolipoprotein E-deficient mice. Nutr Res 28: 335-342. https://doi.org/10.1016/j.nutres.2008.03.010
  27. Ngoc L, Oh YK, Lee YJ, Lee YC. 2018. Effects of Sparassis crispa in medical therapeutics: A systematic review and meta-analysis of randomized controlled trials. Int J Mol Sci 19: 1487. doi:10.3390/ijms19051487.
  28. Qu L, Xin H, Zheng G, Su Y, Ling C. 2012. Hepatoprotective activity of the total saponin from Actinidia valvata Dunn root against carbon tetrachloride-induced liver damage in mice. Evid Based Complement Alternat Med 216061.
  29. Reeves PG, Nielsen FH, Fahey GC Jr. 1993. AIN-93-purified diets for laboratory rodents: Final report of the American institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123: 1939-1951. https://doi.org/10.1093/jn/123.11.1939
  30. Ross R. 1993. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809. https://doi.org/10.1038/362801a0
  31. Ryoo R, Sou HD, Ka KH, Park H. 2013. Phylogenetic relationships of Korean Sparassis latifolia based on morphological and ITS rDNA characteristics. J Microbiol 51: 43-48. https://doi.org/10.1007/s12275-013-2503-4
  32. Takeyama A, Nagata Y, Shirouchi B, Nonaka C, Aoki H, Haraguchi T, Sato M, Tamaya K, Yamamoto, H, Tanaka K. 2018. Dietary Sparassis crispa reduces body fat mass and hepatic lipid levels by enhancing energy expenditure and suppressing lipogenesis in rats. J Oleo Sci 67: 1137-1147. https://doi.org/10.5650/jos.ess18043
  33. Wasser SP. 2014. Medicinal mushroom science: Current perspectives, advances, evidences, and challenges. Biomed J 37: 345-356 https://doi.org/10.4103/2319-4170.138318
  34. Yamamoto K, Kimura T, Sugitachi A, Matsuura N. 2009. Antiangiogenic and anti-metastatic effect of β-1,3-D-glucan purified from hanabiratake, Sparassis crispa. Biol Pharm Bull 32: 259-263. https://doi.org/10.1248/bpb.32.259
  35. Yoon KN, Alam N, Shim MJ, Lee TS. 2012. Hypolipidemic and antiatherogenesis effect of culinary-medicinal pink oyster mushroom, Pleurotus salmoneostramineus L. Vass. (higher basidiomycetes), in rats. Int J Med Mushrooms 14: 27-36. https://doi.org/10.1615/IntJMedMushr.v14.i1.30
  36. Yoon KN, Lee JS, Kim HY, Lee KR, Shin PG, Cheong JC, Yoo YB, Alam N, Ha TM, Lee TS. 2011. Appraisal of antihyperlipidemic activities of Lentinus lepideus in hypercholesterolemic rats. Mycobiol 39: 283-289. https://doi.org/10.5941/MYCO.2011.39.4.283
  37. Zou Y, Li J, Lu C, Wang J, Ge J, Huang Y, Zhang L, Wang Y. 2006. High-fat emulsion induced rat model of nonalcoholic steatohepatitis. Life Sci 79: 1100-1107. https://doi.org/10.1016/j.lfs.2006.03.021